Precipio
Update in progressPRPO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Precipio, Inc. is a healthcare biotechnology company that develops and provides cancer diagnostic products, reagents, and services in the United States. It offers diagnostic blood cancer testing and a range of genetic diagnostic panels under its HemeScreen line. The company also provides IV-Cell, a proprietary culture medium for simultaneous growth of four hematopoietic cell lineages, plus biomarker testing and clinical project services for bio-pharma customers. Based in New Haven, Connecticut.
Company score
- Sentiment
- -0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.41
- Governance
- -0.38
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.20
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Ilan Danieli
- Employees61
- Websitewww.precipiodx.com
Identifiers
- ISINUS74019L5030
- FIGIBBG000C0C3X9
- LEI54930079ULTBRXUQNR89
- CUSIP74019L107
- CIK0001043961